Adults aged≥ 65 years remain at elevated risk for severe COVID-19 disease and have
higher COVID-19–associated hospitalization rates compared with those in younger age …

Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …

Introduction Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-
to-moderate COVID-19 and at high risk of progression to severe disease. Our objective was …

Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in
highest-risk COVID-19 patients during Omicron predominance. Methods Retrospective …

(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-
2019 (COVID-19) and are good candidates for antiviral drugs.(2) Methods: A retrospective …

Simple Summary The results of previous studies may suggest that Nirmatrelvir/Ritonavir,
when evaluated against placebo controls, could potentially be more effective than …

We estimated the proportion of hospitalizations that could have been averted had all eligible
high-risk adults with SARS-CoV-2 infection in a clinical cohort been treated with an oral …

Background The MOVe-OUT (efficacy and safety of molnupiravir [MK-4482] in non-
hospitalized adult participants with COVID-19 [MK-4482-002]) trial reported that the …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Purpose: Immunocompromised individuals, such as those diagnosed with cancer, are at a
significantly higher risk for severe illness and mortality when infected with SARS-CoV-2 …